Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: ‘Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?’ by Xie et al

Carmen Magdalena Gamboa-Alonso; Gabriel Figueroa-Parra; Dionicio Angel Galarza-Delgado

首页> 外文期刊>Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research >Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: ‘Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?’ by Xie et al

【24h】

Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: ‘Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?’ by Xie et al

机译：仍然早期为有风湿病患者的Covid-19抗疟疾药物的明确作用。回应：'羟基氯喹减少了风湿病患者Covid-19的风险：神话或现实？'通过谢等人

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research》 |2021年第1期|共1页
作者
Carmen Magdalena Gamboa-Alonso; Gabriel Figueroa-Parra; Dionicio Angel Galarza-Delgado;
展开▼
作者单位

Servicio de Reumatología;

Servicio de Reumatología;

Servicio de Reumatología;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词
antirheumatic agents; arthritis; rheumatoid; autoimmune diseases; hydroxychloroquine; lupus erythematosus; systemic;

机译：抗逆肿瘤;关节炎;类风湿;自身免疫疾病;羟氯喹;狼疮红斑;系统性;

相似文献

外文文献
中文文献
专利

1. Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality? [J] . Wenhui Xie, Yu Wang, Zhuoli Zhang Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2021,第1期

机译：羟基氯喹减少了风湿病患者Covid-19的风险：神话或现实？
2. Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: ‘COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs’ by Conticini et al [J] . Sara Monti, Carlomaurizio Montecucco Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2021,第2期

机译：患有风湿病患者的Covid-19患病率：需要等待大型合作研究的结果。回应：'Covid-19肺炎，伴有生物和有针对性合成抗尿剂药物的大型患者，Conticini等
3. Response to: ‘The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients’ by Favalli et al [J] . Vasco C Rom?o, Ana Rita Cruz-Machado, Jo?o Eurico Fonseca Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2021,第5期

机译：回应：'antimalarials在Covid-19中的作用：来自Favalli等人的群体群体的观察数据
4. A Simple Bayesian Method for Evaluating Whether Data From Patients With Rheumatic Diseases Who Have Been Under Chronic Hydroxychloroquine Medication Since Before the COVID-19 Outbreak Can Speak to Hydroxychloroquines Prophylactic Effect Against Infection With SARS-CoV-2 [O] . Serban C. Musca 2020

机译：一种简单的贝叶斯方法用于评估来自慢性羟基氯喹药物的风湿性疾病的数据是否从Covid-19爆发之前达到慢性羟基氯喹药物可以与SARS-COV-2的羟基氯喹对羟基氯喹的预防效果交谈
5. Response to: ‘Correspondence on ‘Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases’’ by Schulze-Koops et al [O] . Dalifer Dayanira Freites Nuñez, Leticia Leon, Arkaitz Mucientes, 2020

机译：回应：舒兹-Koops等人患者患者与Covid-19相关的医院入学危险因素的响应

Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: ‘Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?’ by Xie et al

著录项

相似文献

相关主题

期刊订阅